Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma
NCT03902184 · View on ClinicalTrials.gov ↗
Study Summary
This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
Conditions Studied
Interventions
- BIOLOGICAL IPH4102
Study Locations (20)
California
- University of California, Los Angeles (UCLA) - Medical Center — Los Angeles
- Irvine Medical Center — Orange
- Stanford University — Stanford
Pennsylvania
- University of Pennsylvania — Philadelphia
- Thomas Jefferson University — Philadelphia
- University of Pittsburgh School of Medicine — Pittsburgh
Other
- Universitätsklinik für Dermatologie Medizinische Universität Graz — Graz
- Medizinische Universitaet Wien — Vienna
- Institut Jules Bordet — Brussels
Florida
- Moffitt Cancer Center — Tampa
- University of South Florida — Tampa
New York
- Universal Dermatology, PLLC68 — Fairport
- Columbia University Department of Dermatology — New York
Alabama
- University of Alabama at Birmingham — Birmingham
Illinois
- Northwestern University The Feinberg School of Medicine — Chicago
Massachusetts
- Dana-Farber Cancer Institute — Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2019-05-22 |
| Est. Completion | 2026-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03902184
The ClinicalTrials.gov registry entry for NCT03902184 describes a study currently listed as active not recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 170 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Innate Pharma, which has 63 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 3 conditions, with Lymphoma, T-Cell appearing as the primary indexed condition, and to 1 intervention — of which IPH4102 is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT03902184 reports 20 study locations spanning 12 distinct geographic areas — top geographies include California, Pennsylvania, Other. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT03902184 about?
NCT03902184 is a clinical study titled "IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma". This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.
What is the current status of trial NCT03902184?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2019-05-22. Estimated completion is 2026-01-31.
What conditions does trial NCT03902184 study?
This clinical trial studies the following conditions: Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT03902184?
The interventions under investigation include: IPH4102 (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT03902184?
This trial is sponsored by Innate Pharma, which has 63 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT03902184 being conducted?
This trial has 20 study locations across Alabama, California, Florida, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.